{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:07:44Z","timestamp":1692972464278},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The role of hematopoietic cell transplantation (HCT) for indolent lymphoma has evolved over the last 5 years with the availability of novel low-toxicity therapies and a better understanding of the prognosis of these entities. However, despite numerous treatment options for patients with follicular lymphoma, none are thought to be curative, and many require ongoing therapy with chronic toxicity. Historical trials indicate that autologous HCT as initial consolidation leads to improved progression-free survival, but not overall survival (OS) and, thus, is not typically recommended. However, autologous HCT for chemosensitive relapse can be carried out with \u223c1% early mortality risk, affording disease control lasting a median of 3 to 5 years and the potential to improve OS. These results may compare favorably in efficacy, toxicity, and cost vs multiple sequential novel therapies with shorter durations of benefit. Recent data indicate that autologous HCT in follicular lymphoma patients with early initial progression will result in more than one third being alive and without relapse at 5 years, leading to improved OS when used within a year of the first recurrence. Unlike other available therapies, allogeneic HCT has the potential to cure up to one half of those transplanted with indolent B-cell non-Hodgkin lymphoma, although the risks need to be recognized and appropriate patient and donor selection is critical to ensure the best outcomes. HCT continues to remain a viable option in the current era of multiple targeted agents.<\/jats:p>","DOI":"10.1182\/hematology.2019000033","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T10:12:39Z","timestamp":1575627159000},"page":"287-293","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Where does transplant fit in the age of targeted therapies?"],"prefix":"10.1182","volume":"2019","author":[{"given":"Victor A.","family":"Chow","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, University of Washington, Seattle, WA; and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Washington, Seattle, WA; and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"6","key":"2019120610100825300_B1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2019120610100825300_B2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2019120610100825300_B3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study [published correction appears in J Clin Oncol. 2016 Apr 20;34(12):1430]","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019120610100825300_B4","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"2019120610100825300_B5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"key":"2019120610100825300_B6","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 Study [published online ahead of print 10 July 2019]","author":"Luminari","journal-title":"Blood"},{"issue":"11","key":"2019120610100825300_B7","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019120610100825300_B8","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2019120610100825300_B9","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019120610100825300_B10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019120610100825300_B11","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019120610100825300_B12","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2019120610100825300_B13","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019120610100825300_B14","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019120610100825300_B15","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019120610100825300_B16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.hoc.2018.05.013","article-title":"High-dose therapy and hematopoietic stem cell transplantation in Waldenstr\u00f6m macroglobulinemia","volume":"32","author":"Kyriakou","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"2019120610100825300_B17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"2019120610100825300_B18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjh.15454","article-title":"High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO","volume":"182","author":"Avivi","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"2019120610100825300_B19","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/10428190701583983","article-title":"The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation","volume":"48","author":"Keeney","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019120610100825300_B20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/10428194.2014.911866","article-title":"Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity","volume":"56","author":"Phipps","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019120610100825300_B21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00259-014-2896-2","article-title":"PET\/CT before autologous stem cell transplantation predicts outcome in refractory\/relapsed follicular lymphoma","volume":"42","author":"Alcantara","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3 suppl","key":"2019120610100825300_B22","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1016\/j.bbmt.2018.12.636","article-title":"A retrospective validation of three standard prognostic instruments used to inform decisions regarding autologous and allogeneic stem cell transplantation","volume":"25","author":"Seegars","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019120610100825300_B23","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a national LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019120610100825300_B24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019120610100825300_B25","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/bmt.2017.88","article-title":"Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party","volume":"52","author":"Bento","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019120610100825300_B26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","article-title":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT","volume":"5","author":"Kanate","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"2019120610100825300_B27","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"issue":"20","key":"2019120610100825300_B28","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN Lymphoma Outcomes Project","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"2019120610100825300_B29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019120610100825300_B30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2018018531","article-title":"Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"2019120610100825300_B31","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response","volume":"17","author":"Tomblyn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"33","key":"2019120610100825300_B32","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstr\u00f6m macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019120610100825300_B33","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1080\/10428194.2018.1452220","article-title":"Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience","volume":"59","author":"Dholaria","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019120610100825300_B34","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.31264","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR","volume":"124","author":"Sureda","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"2019120610100825300_B35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13045-017-0487-y","article-title":"Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma","volume":"10","author":"Epperla","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2019120610100825300_B36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2017.10.011","article-title":"Fludarabine and busulfan versus fludarabine, cyclophosphamide, and rituximab as reduced-intensity conditioning for allogeneic transplantation in follicular lymphoma","volume":"24","author":"Epperla","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019120610100825300_B37","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"26","key":"2019120610100825300_B38","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: A Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019120610100825300_B39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbmt.2014.10.024","article-title":"Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation","volume":"21","author":"Cassaday","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2019120610100825300_B40","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019120610100825300_B41","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2006.06.0673","article-title":"Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia","volume":"24","author":"Kalaycio","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019120610100825300_B42","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019120610100825300_B43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"issue":"2","key":"2019120610100825300_B44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2012.133","article-title":"Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2019120610100825300_B45","first-page":"1","article-title":"Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States","volume":"8","author":"Cho","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019120610100825300_B46","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","article-title":"Reduced-intensity allografting as first transplantation approach in relapsed\/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors","volume":"21","author":"Klyuchnikov","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019120610100825300_B47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/bmt.2015.223","article-title":"Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma","volume":"51","author":"Klyuchnikov","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2019120610100825300_B48","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/287\/1546066\/hem2019000033c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/287\/1546066\/hem2019000033c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T10:12:58Z","timestamp":1575627178000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/287\/422587\/Where-does-transplant-fit-in-the-age-of-targeted"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000033","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}